The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases).
Traditionally one of the most volatile sectors in the market, there are a number of top biotech stocks investors can look at for massive potential upside over the course of the next year. For this piece, I’ve picked three companies that have shown the ability to double in short order, as a way to play very bullish sentiment materializing in this sector in 2026. Notably, I’m not going to be focused on many of the large-cap names in this sector, and focus on small to mid-cap names in this sector with strong catalysts to kick off 2026.
Without further ado, let’s dive in!
Denali Therapeutics (DNLI)
Focusing on rare neurodegenerative and lysosomal diseases, Denali Therapeutics (NASDAQ:DNLI) is a stock that many investors may rightly be cautious of, from the perspective of companies that have the potential to surge. That’s due in part to the company’s five-year return of -75%, signaling many in the market have moved away from this stock.
Now, it’s also true that a company that falls by such an amount over a five year period could snap back nicely, if the company’s core product portfolio is validated by the market. I think Denali is among the more unique companies in the biologics space, using its patented transport vehicle platform to move biologics across the blood-brain barrier.
The company’s key programs could provide candidates for patients with Hunter Syndrome and other rare diseases, which could provide big upside of clinical trials perform as expected. Key earnings drivers for this year are milestone payments and collaboration revenue from Peters, if programs hit predefined clinical or regulatory milestones. For those who believe in the quality of the company’s R&D team, and the key underserved diseases Denali is targeting, this is a sleeper pick in the biotech sector which could provide big upside in 2026.
Nuvalent (NUVL)
Nuvalent (NASDAQ:NUVL) is another company I think has the potential to double this year.
This precision oncology company has a portfolio of cancer drugs targeting lung and other forms of cancer still in trial stages of development. But if these drugs are validated by upcoming studies, and the FDA approves further trials, it’s possible Nuvalent could be squarely positioned in the “best-in-class” upgrade trade.
Of course, the data will ultimately need to cooperate with investors’ hopes. And it’s true that no matter which biotech company investors are looking at, there’s some level of hope built into these companies’ stock prices, and their binary outcomes which drive stock price movements. But with solid R&D spending offset by a reasonable spending runway, Nuvalent is a top option for investors looking for a stock with speculative upside over the course of this year. If we see targeted oncology names re-rated higher this year on the back of superior data, I’d posit that Nuvalent has the potential to be one of the biggest potential winners in the market in such an environment.
Xenon Pharmaceuticals (XENE)
Let’s wrap up this list with another top biotech stock I think has big upside potential in 2026, in Xenon Pharmaceuticals (NASDAQ:XENE).
Xenon is a neurology-focused biotech company with a leading seizure treatment (azetukalner) the most-watched drug in the company’s portfolio. This drug words to control seizures via modulation neuronal excitability, providing some compelling early results compared to the current gamut of anti-seizure therapies currently on the market. With other indications such as epilepsy and psychiatric conditions creating a broad optionality profile for investors, this is a company I think could have asymmetric upside if results come in as expected.
More R&D invemstne will be needed to push these drugs forward in gaining approval from regulators. That said, top-line trail readouts have the potential to meaningfully affect the company’s equity value, which I’d suggest could certainly double if the phase 2/3 trials go as expected.
Additionally, Xenon’s ability to potentially explore additional markets such as mood-related indications (such as depression) could provide a massive target market, if regulators agree. This is a stock I think investors may benefit from taking a flyer on.
Top Gaining Stocks
Top Losing Stocks